{"id":"aliskiren-150","safety":{"commonSideEffects":[{"rate":"9","effect":"Diarrhea"},{"rate":"7","effect":"Headache"},{"rate":"4","effect":"Dizziness"},{"rate":"3","effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1639","moleculeType":"Small molecule","molecularWeight":"551.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting renin directly at the top of the RAAS cascade, aliskiren reduces the formation of angiotensin II, a potent vasoconstrictor and aldosterone stimulator. This leads to vasodilation, reduced sodium retention, and lower blood pressure. Unlike ACE inhibitors or ARBs that block downstream steps, direct renin inhibition provides a more complete blockade of the RAAS.","oneSentence":"Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system (RAAS) by preventing renin from converting angiotensinogen to angiotensin I.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:20.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Diabetic nephropathy (in combination with losartan)"}]},"trialDetails":[{"nctId":"NCT04183101","phase":"PHASE2","title":"Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2020-10-01","conditions":"C3 Glomerulopathy, Membranoproliferative Glomerulonephritis, Complement Abnormality","enrollment":30},{"nctId":"NCT00424541","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hypertension","enrollment":34},{"nctId":"NCT00765947","phase":"PHASE4","title":"Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Essential Hypertension ( Mild to Moderate)","enrollment":256},{"nctId":"NCT01519635","phase":"PHASE4","title":"Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2011-10","conditions":"Hypertension","enrollment":24},{"nctId":"NCT01103245","phase":"PHASE1","title":"Aldosterone and the Metabolic Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-03","conditions":"Metabolic Diseases, Diabetes Mellitus, Endocrine System Diseases","enrollment":69},{"nctId":"NCT01235910","phase":"PHASE4","title":"Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2011-05","conditions":"Hypertension, Cardiac Transplantation","enrollment":1},{"nctId":"NCT00974922","phase":"PHASE4","title":"Vitamin D Deficiency in Patients With Hypertension","status":"TERMINATED","sponsor":"UConn Health","startDate":"2009-08","conditions":"Vitamin D Deficiency, Hypertension","enrollment":40},{"nctId":"NCT01461499","phase":"PHASE4","title":"Shiga Microalbuminuria Reduction Trial-2","status":"COMPLETED","sponsor":"Shiga University","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":237},{"nctId":"NCT01252238","phase":"NA","title":"Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-06","conditions":"Insulin Sensitivity, Aortic Compliance, Diastolic Function","enrollment":24},{"nctId":"NCT01318395","phase":"PHASE3","title":"Aliskiren on Retinal Vasculature Treatment Study","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-05","conditions":"Arterial Hypertension","enrollment":56},{"nctId":"NCT00818779","phase":"PHASE4","title":"Direct Renin Inhibition Effects on Atherosclerotic Biomarkers","status":"COMPLETED","sponsor":"Texas Tech University Health Sciences Center","startDate":"2008-01","conditions":"Coronary Artery Disease, Type 2 Diabetes Mellitus","enrollment":38},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT00994253","phase":"PHASE4","title":"Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2009-08","conditions":"Hypertension, Diabetes Type 2","enrollment":""},{"nctId":"NCT03115853","phase":"PHASE4","title":"The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-06","conditions":"High Blood Pressure","enrollment":31},{"nctId":"NCT00219076","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":"Hypertension","enrollment":504},{"nctId":"NCT00219011","phase":"PHASE3","title":"\"ALOFT - Aliskiren Observation of Heart Failure Treatment\": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Heart Failure","enrollment":280},{"nctId":"NCT00219180","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension","enrollment":1797},{"nctId":"NCT01417104","phase":"PHASE2, PHASE3","title":"Aliskiren Effect on Aortic Plaque Progression","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2009-10","conditions":"Atherosclerosis","enrollment":71},{"nctId":"NCT01437943","phase":"PHASE4","title":"Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-04","conditions":"Kidney Disease, Kidney Failure, Chronic","enrollment":10},{"nctId":"NCT01056731","phase":"PHASE4","title":"A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"High Blood Pressure","enrollment":253},{"nctId":"NCT01237873","phase":"PHASE3","title":"Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Essential Hypertension","enrollment":150},{"nctId":"NCT01070030","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Stage II Hypertension","enrollment":230},{"nctId":"NCT00387517","phase":"PHASE3","title":"Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":726},{"nctId":"NCT01060865","phase":"PHASE4","title":"Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements","status":"TERMINATED","sponsor":"Meir Medical Center","startDate":"2010-03","conditions":"Blood Pressure, High","enrollment":50},{"nctId":"NCT00853658","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Heart Failure","enrollment":7064},{"nctId":"NCT00171405","phase":"PHASE3","title":"A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension","enrollment":250},{"nctId":"NCT00219167","phase":"PHASE3","title":"A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-04","conditions":"Hypertension","enrollment":355},{"nctId":"NCT00778921","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Hypertension","enrollment":847},{"nctId":"NCT00787605","phase":"PHASE4","title":"Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension, Diabetes Mellitus","enrollment":860},{"nctId":"NCT00739596","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Hypertension","enrollment":332},{"nctId":"NCT01827202","phase":"PHASE4","title":"RAS Quantification in Patients With Aliskiren or Candesartan","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-12","conditions":"Hypertension, Chronic Kidney Disease, Proteinuria","enrollment":24},{"nctId":"NCT01151410","phase":"PHASE3","title":"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Hypertension","enrollment":208},{"nctId":"NCT00856960","phase":"PHASE1","title":"The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT01090310","phase":"PHASE3","title":"Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Non-infectious Uveitis","enrollment":86},{"nctId":"NCT01150357","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension","enrollment":267},{"nctId":"NCT00922311","phase":"PHASE4","title":"Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2009-07","conditions":"IgA Nephropathy","enrollment":25},{"nctId":"NCT01480791","phase":"PHASE2","title":"Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2012-01","conditions":"Hypertension, Diabetes","enrollment":""},{"nctId":"NCT02446548","phase":"NA","title":"Influence of Aliskiren on Albuminuria After Kidney Transplantation","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2013-03","conditions":"Albuminuria","enrollment":18},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01425242","phase":"NA","title":"Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Hypertension, Abdominal Aortic Aneurysm","enrollment":3},{"nctId":"NCT01176032","phase":"PHASE4","title":"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension, Left Ventricle Hypertrophy","enrollment":74},{"nctId":"NCT01129557","phase":"PHASE4","title":"Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease","status":"TERMINATED","sponsor":"Columbia University","startDate":"2009-09","conditions":"Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis","enrollment":46},{"nctId":"NCT00549757","phase":"PHASE3","title":"Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":8606},{"nctId":"NCT01259297","phase":"PHASE3","title":"A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Cardiovascular Events","enrollment":2336},{"nctId":"NCT00386607","phase":"PHASE3","title":"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Hypertension","enrollment":601},{"nctId":"NCT01432106","phase":"PHASE1","title":"The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2011-02","conditions":"Hypertension, Metabolic Syndrome","enrollment":""},{"nctId":"NCT00894387","phase":"PHASE3","title":"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Acute Decompensated Heart Failure, Congestive Heart Failure","enrollment":1639},{"nctId":"NCT00961207","phase":"PHASE4","title":"Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients","status":"TERMINATED","sponsor":"Cook County Health","startDate":"2009-08","conditions":"Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes","enrollment":2},{"nctId":"NCT01893788","phase":"PHASE4","title":"Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy","status":"UNKNOWN","sponsor":"Nagoya University","startDate":"2013-04","conditions":"Hypertensive Left Ventricular Hypertrophy","enrollment":100},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT01067326","phase":"PHASE3","title":"The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2010-02","conditions":"Endothelial Dysfunction","enrollment":22},{"nctId":"NCT01302899","phase":"PHASE2","title":"To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Non-diabetic Nephropathy","enrollment":8},{"nctId":"NCT00927394","phase":"PHASE4","title":"Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-05","conditions":"Hypertension","enrollment":1143},{"nctId":"NCT01125514","phase":"PHASE2","title":"A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"Heart Failure","enrollment":37},{"nctId":"NCT00923156","phase":"PHASE2","title":"Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Heart Failure","enrollment":123},{"nctId":"NCT00414609","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Myocardial Infarction","enrollment":820},{"nctId":"NCT01394770","phase":"PHASE4","title":"Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2009-09","conditions":"Hypertension, Dialysis","enrollment":350},{"nctId":"NCT01635387","phase":"PHASE4","title":"RAAS Inhibitor Drugs in Dialysis Patients","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2010-02","conditions":"Hypertension, End Stage Renal Disease","enrollment":350},{"nctId":"NCT01237223","phase":"PHASE3","title":"Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Essential Hypertension","enrollment":1342},{"nctId":"NCT00853957","phase":"PHASE4","title":"Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":443},{"nctId":"NCT01042392","phase":"PHASE4","title":"Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-11","conditions":"Essential Hypertension","enrollment":506},{"nctId":"NCT01138423","phase":"PHASE4","title":"Treatment of Adiposity Related hypErTension (TARGET)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2010-08","conditions":"Hypertension, Abdominal Obesity, Metabolic Syndrome","enrollment":32},{"nctId":"NCT01080768","phase":"PHASE2","title":"Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Hypertension, Ankle Edema","enrollment":31},{"nctId":"NCT00260923","phase":"PHASE3","title":"A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Hypertension","enrollment":641},{"nctId":"NCT00219037","phase":"PHASE3","title":"Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-06","conditions":"Hypertension","enrollment":1955},{"nctId":"NCT00219128","phase":"PHASE3","title":"A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Hypertension","enrollment":671},{"nctId":"NCT00797862","phase":"PHASE3","title":"Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":1254},{"nctId":"NCT00865020","phase":"PHASE4","title":"Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":822},{"nctId":"NCT00631917","phase":"PHASE4","title":"A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Hypertension","enrollment":774},{"nctId":"NCT00841672","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-01","conditions":"Moderate to Severe Hypertension","enrollment":485},{"nctId":"NCT00706134","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Hypertension","enrollment":756},{"nctId":"NCT00819767","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":68},{"nctId":"NCT00654875","phase":"PHASE4","title":"Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-03","conditions":"Essential Hypertension","enrollment":328},{"nctId":"NCT01184599","phase":"PHASE4","title":"A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2010-06","conditions":"Glomerulonephritis, IGA, Hypertension","enrollment":30},{"nctId":"NCT00942994","phase":"PHASE4","title":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Hypertension","enrollment":412},{"nctId":"NCT00739973","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-09","conditions":"Hypertension","enrollment":2694},{"nctId":"NCT00705575","phase":"PHASE3","title":"Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06","conditions":"Hypertension","enrollment":688},{"nctId":"NCT00219141","phase":"PHASE3","title":"Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-10","conditions":"Hypertension, Left Ventricular Hypertrophy, Overweight","enrollment":460},{"nctId":"NCT00542269","phase":"PHASE4","title":"Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-03","conditions":"Hypertension With Metabolic Syndrome","enrollment":178},{"nctId":"NCT00765674","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":1191},{"nctId":"NCT00809926","phase":"PHASE4","title":"8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-01","conditions":"Stage 2 Hypertension","enrollment":451},{"nctId":"NCT00409578","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Post Acute Coronary Syndrome, Myocardial Ischemia","enrollment":1101},{"nctId":"NCT00760266","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":451},{"nctId":"NCT00368277","phase":"PHASE3","title":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Hypertension","enrollment":901},{"nctId":"NCT00529451","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Hypertension","enrollment":1613},{"nctId":"NCT00772577","phase":"PHASE4","title":"Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Hypertension","enrollment":386},{"nctId":"NCT00797316","phase":"PHASE4","title":"Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":532},{"nctId":"NCT00402103","phase":"PHASE3","title":"An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Hypertension","enrollment":556},{"nctId":"NCT01305850","phase":"PHASE4","title":"The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2010-07","conditions":"Peritoneal Membrane Failure","enrollment":100},{"nctId":"NCT01298258","phase":"NA","title":"Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2010-07","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT01040494","phase":"PHASE4","title":"Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-01","conditions":"Congestive Heart Failure","enrollment":60},{"nctId":"NCT00732407","phase":"NA","title":"Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2008-09","conditions":"Diabetes Mellitus, Atherosclerosis","enrollment":40},{"nctId":"NCT00416728","phase":"PHASE1","title":"Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aliskiren 150","genericName":"Aliskiren 150","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aliskiren 150 is a medication used to treat conditions such as Heart Failure, Hypertension, End Stage Renal Disease, and Stage 2 Hypertension. It is a direct renin inhibitor, which means it works by blocking the action of renin, an enzyme involved in the regulation of blood pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}